**Amendments to Claims:**

This listing of claims will replace all prior versions and listings in the application:

**Listing of Claims:**

1-88.(Canceled)

89. (Previously Presented) The composition according to claim 101, wherein the antigen is a microorganism.

90. (Canceled)

91. (Previously Presented) The composition according to claim 89, wherein the antigen is a polypeptide.

92. (Previously Presented) The composition according to claim 89, wherein the antigen is a peptide.

93. (Canceled)

94. (Previously Presented) The composition according to claim 101, wherein the antigen is a mycobacterium.

95. (Previously Presented) The composition according to claim 94, wherein the mycobacterium is BCG.

96-98. (Canceled)

99. (Previously Presented) The pharmaceutical composition according to claim 116, wherein the antigen-activated dendritic cells express an amount of the fragmented antigen to provide between about 1 to 100 micrograms of the fragmented antigen in said pharmaceutical composition.

100. (Canceled)

101. (Currently Amended) An *in vitro* composition comprising antigen-activated dendritic cells presenting fragmented antigen and derived from an *in vitro* culture of an enriched and expanded population of proliferating dendritic cell precursors by a method comprising:

providing a tissue source comprising dendritic cell precursors;

optionally treating the tissue source comprising dendritic cell precursors to increase the proportion of dendritic cell precursors;

culturing the tissue source on a substrate in a culture medium comprising GM-CSF to obtain ~~cell clusters;~~

~~subculturing the cell clusters to produce~~ cell aggregates comprising proliferating dendritic cell precursors; and

subculturing the cell aggregates at least one time to enrich the proportion of dendritic cell precursors;

wherein the dendritic cell precursors are cultured *in vitro* in the presence of an antigen for a time sufficient to allow the antigen to be fragmented and presented.

102. (Canceled)

103. (Previously Presented) The pharmaceutical composition according to claim 116, wherein the pharmaceutical composition comprises from about $1x10^6$ to $1x10^7$ antigen activated dendritic cells.

104. (Previously Presented) The composition according to claim 101, wherein the tissue source is blood.

105. (Previously Presented) The composition according to claim 101, wherein the tissue source is bone marrow.

106. (Previously Presented) The composition according to claim 101, wherein GM-CSF is present in the culture medium at a concentration of about 1-1000 U/ml.

107. (Previously Presented) The composition according to claim 104, wherein the concentration of GM-CSF in the culture medium is about 30-100 U/ml.

108. (Currently Amended) The composition according to claim 105, wherein the concentration of GM-CSF in the culture medium is about ~~50-1000~~ 400-800 U/ml.

109. (Previously Presented) The composition according to claim 101, wherein the cell aggregates are blood derived and are subcultured from about one to five times.

110. (Currently Amended) The composition according to claim 101, wherein the cell aggregates are subcultured one to five times ~~every 3 to 30 days~~.

111. (Currently Amended) The composition according to claim 101, wherein the ~~claim~~ culture medium is selected from the group consisting of RPMI 1640, DMEM and α-MEM, and wherein the culture medium is supplemented with serum.

112. (Previously Presented) The composition according to claim 104, wherein the tissue source is treated to remove red blood cells.

113. (Previously Presented) The composition according to claim 105, wherein the tissue source is treated to remove B cells and granulocytes.

114. (Canceled)

115. (Previously Presented) The composition according to claim 101, wherein said fragmented antigen is presented by the dendritic cells on MHC class I or MHC class II molecules.

116. (Previously Presented) A pharmaceutical composition comprising a therapeutically effective amount of the composition according to claim 101.

117. (Previously Presented) The composition according to claim 94, wherein the mycobacterium is a tuberculosis bacteria.

118. (Previously Presented) The composition according to claim 101, wherein the dendritic cell precursors are cultured in the presence of antigen for between 1-48 hours.

119. (Previously Presented) The composition according to claim 118, wherein the dendritic cell precursors are cultured in the presence of antigen for about 20 hours.

120. (Previously Presented) An *in vitro* composition comprising antigen-activated dendritic cells, wherein said antigen-activated dendritic cells are derived from an *in vitro* culture of a population of enriched and expanded proliferating precursor cells which were contacted *in vitro* with antigen in the presence of GM-CSF for a sufficient time for antigen fragmentation and presentation to occur.

121. (Previously Presented) The composition of claim 101, wherein the cell aggregates are serially subcultured one to five times.

122. (Canceled)

123. (New) An *in vitro* composition comprising at least 1 x $10^6$ antigen-activated dendritic cells presenting fragmented antigen and derived from an *in vitro* culture of an enriched and expanded population of proliferating dendritic cell precursors by a method comprising:

providing a tissue source from a single donor comprising dendritic cell precursors;

optionally treating the tissue source comprising dendritic cell precursors to increase the proportion of dendritic cell precursors;

culturing the tissue source on a substrate in a culture medium comprising GM-CSF to obtain cell aggregates comprising proliferating dendritic cell precursors; and

subculturing the cell aggregates at least one time to enrich the proportion of dendritic cell precursors;

wherein the dendritic cell precursors are derived from said single donor and wherein the dendritic cell precursors are cultured *in vitro* in the presence of an antigen for a time sufficient to allow the antigen to be fragmented and presented.

124. (New) The composition according to claim 123, wherein the tissue source is blood.

125. (New) The composition according to claim 123, wherein the tissue source is bone marrow.

126. (New) The composition according to claim 123, wherein GM-CSF is present in the culture medium at a concentration of about 1-1000 U/ml.

127. (New) The composition according to claim 123, wherein the concentration of GM-CSF in the culture medium is about 30-100 U/ml.

128. (New) The composition according to claim 123, wherein the concentration of GM-CSF in the culture medium is about 50-1000 U/ml.

129. (New) The composition according to claim 123, wherein the cell aggregates are blood derived and are subcultured from about one to five times.

130. (New) The composition according to claim 124, wherein the tissue source is treated to remove red blood cells.

131. (New) The composition according to claim 125, wherein the tissue source is treated to remove B cells and granulocytes.

132. (New) The composition according to claim 101, wherein said fragmented antigen is presented by the dendritic cells on MHC class I or MHC class II molecules.

133. (New) A pharmaceutical composition comprising a therapeutically effective amount of the composition according to claim 123.

134. (New) The composition according to claim 123, wherein the antigen is a mycobacterium.

135. (New) The composition according to claim 123, wherein the mycobacterium is BCG.

136. (New) The composition according to claim 123, wherein the dendritic cell precursors are cultured in the presence of antigen for between 1-48 hours.

137. (New) The composition according to claim 136, wherein the dendritic cell precursors are cultured in the presence of antigen for about 20 hours.

138. (New) The composition of claim 123, wherein said culture medium further comprises TNF-α.

139. (New) The composition of claim 138, wherein said culture medium comprises TNF-α at a concentration of from 5 to 500 U/ml.

140. (New) The composition of claim 101, wherein said culture medium further comprises TNF-α.

141. (New) The composition of claim 140, wherein said culture medium comprises TNF-α at a concentration of from 5 to 500 U/ml.